MK8033 HCL

Description: MK-8033 HCl is a novel, potent, selective, ATP competitive small-molecule, dual inhibitor of c-Met/Ron (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer. The design of MK-8033 was based on the desire to reduce time-dependent inhibition of CYP3A4 (TDI) by members of this structural class. A novel two-step protocol for the synthesis of benzylic sulfonamides was developed to access MK-8033 and analogues. Importantly, MK-8033 provides full inhibition of tumor growth in a c-Met amplified (GTL-16) subcutaneous tumor xenograft model and may have an advantage over inactive form kinase inhibitors due to equal potency against a panel of oncogenic activating mutations of c-Met in contrast to c-Met inhibitors without preferential binding to the active kinase conformation.

References: J Med Chem. 2013 Mar 28; 56(6):2294-310; J Thorac Oncol. 2012 Aug; 7(8):1211-7.

Related CAS#:1001917-37-8 (free base)